REGULATORY

• Finance Minister Backs Further Debate on Low-Risk Medicines: CEFP Minutes
  May 29, 2026

• LDP HQ Finalizes Recommendations ahead of Growth Strategy
  May 29, 2026

• Japan Eyes Broader Healthcare Measures Addressing Sex-Based Health Issues
  May 28, 2026

• MHLW Panel Deems 4 More “Drug Loss” Products as High-Need
  May 27, 2026

• LDP Panel OKs Immunization Act Bill Aimed at Beyfortus NIP Use
  May 27, 2026

• Japan Selects JN.1 Substrains for COVID Vaccines in 2026-2027 Season
  May 27, 2026

• Ex-Minister Kato Preparing Parliamentary Group on Diabetes Issues
  May 27, 2026

• LDP Lawmakers’ League Urges Economic Efficiency in Drug Use
  May 27, 2026

• US Calls Out Japan’s Market Expansion Re-Pricing Rules as “Unfair”: IP Report
  May 26, 2026

• CEA Review Group Holds First Meeting, Technical Debate Yet to Begin
  May 26, 2026

• AstraZeneca’s Oral SERD, MSD RSV Antibody Clear Japan Panel Review
  May 26, 2026

• Japan Mulls Target on “Social Security Burden Rate” after CEFP Call
  May 25, 2026

• Ishin Deepens Debate on Healthcare Macroeconomic Indexing
  May 25, 2026

• Update: Tavneos Slapped with Blue Letter Action in Japan over Liver Injury Risk
  May 22, 2026

• Blister Pack Supplies Seen Returning to Normal: Health Minister
  May 22, 2026

• LDP “Eto” Study Group Submits Honebuto Proposal to Health Minister
  May 22, 2026

• Oncolys’ Telomelysin Wins Backing from Japan Panel
  May 22, 2026

• MHLW Moves Toward Immunization Act Revision for RSV Antibody Drugs
  May 21, 2026

• Japan Approves Nonprescription Cialis, Rozerem
  May 21, 2026

• MHLW Panel Clarifies Roles in Vaccine Policy Review Process
  May 21, 2026

ページ

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• …
• Next ›
• 最終 »